Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10,443.00 GBX | +0.49% |
|
-3.62% | -0.40% |
Jun. 02 | ASTRAZENECA : Buy rating from JP Morgan | ZD |
Jun. 02 | UK's FTSE 100 closes around flat as staples, healthcare losses eclipse energy gains | RE |
Business description: AstraZeneca PLC
- product sales (94.2%). Net sales break down by treatment area between oncology (39.8%), cardiovascular, renal and metabolic diseases (24.4%), respiratory and autoimmune diseases (14.6%), and other (21.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (5.8%).
Net sales are distributed geographically as follows: the United Kingdom (8.8%), Europe (21.6%), the United States (40.3%), Americas (5.9%) and Africa/Asia/Australia (23.4%).
Number of employees: 94,300
Sales by Activity: AstraZeneca PLC
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Biopharmaceuticals | 26.62B | 37.42B | 44.35B | 45.81B | 54.07B |
Geographical breakdown of sales: AstraZeneca PLC
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
United States | 8.96B | 12.05B | 17.28B | 18.12B | 21.81B |
China | 5.34B | 6B | 5.74B | 5.87B | 6.42B |
United Kingdom | 1.74B | 3.24B | 3.12B | 3.37B | 4.74B |
Other Rest of Europe | 1.39B | 1.95B | 2.71B | 3.11B | 3.66B |
Japan | 2.57B | 3.4B | 3.99B | 3.64B | 3.45B |
Germany | 937M | 1.49B | 1.9B | 2.1B | 2.52B |
Other Asia, Africa & Australasia | 1.53B | 2.38B | 2.41B | 2.04B | 2.33B |
Sweden | 1.03B | 2.32B | 1.72B | 1.7B | 2.29B |
Other Americas | 761M | 1.2B | 1.18B | 1.68B | 2.25B |
France | 653M | 915M | 1.11B | 1.15B | 1.28B |
Spain | 398M | 578M | 738M | 847M | 994M |
Italy | 431M | 577M | 735M | 813M | 949M |
Canada | 596M | 772M | 1.17B | 967M | 937M |
Australia | 282M | 547M | 571M | 390M | 439M |
Executive Committee: AstraZeneca PLC
Manager | Title | Age | Since |
---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 65 | 2012-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 51 | 2021-07-31 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 2023-07-31 |
Jeffrey Pott
CMP | Compliance Officer | - | - |
Chief Tech/Sci/R&D Officer | - | 2023-05-17 |
Composition of the Board of Directors: AstraZeneca PLC
Director | Title | Age | Since |
---|---|---|---|
Director/Board Member | 69 | 1999-04-05 | |
Pascal Soriot
BRD | Director/Board Member | 65 | 2012-09-30 |
Philip Broadley
BRD | Director/Board Member | 64 | 2017-04-26 |
Nazneen Rahman
BRD | Director/Board Member | - | 2017-05-31 |
Sherilyn McCoy
BRD | Director/Board Member | 66 | 2017-09-30 |
Shu Kam Mok
BRD | Director/Board Member | 64 | 2018-12-31 |
Michel Demaré
CHM | Chairman | 68 | 2023-04-26 |
Euan Ashley
BRD | Director/Board Member | - | 2020-09-30 |
Diana Layfield
BRD | Director/Board Member | - | 2020-10-31 |
Aradhana Sarin
BRD | Director/Board Member | 51 | 2021-07-31 |
Holdings: AstraZeneca PLC
Name | Equities | % | Valuation |
---|---|---|---|
18,750,000 | 75% | 1,745,223,562 $ | |
35,043,578 | 9.84% | 1,069,737,809 $ | |
HBM HOLDINGS LIMITED 9.96% | 76,271,762 | 9.96% | 86,859,045 $ |
NIOX GROUP PLC 16.61% | 66,093,108 | 16.61% | 59,360,203 $ |
CELLECTIS S.A. 22.19% | 16,000,000 | 22.19% | 24,194,400 $ |
INNATE PHARMA 8.93% | 7,485,500 | 8.93% | 16,774,856 $ |
387,329 | 6.35% | 12,289,949 $ |
Company details: AstraZeneca PLC
AstraZeneca PLC
Cambridge Biomedical Campus 1 Francis Crick Avenue
CB2 0AA, Cambridge
+44 20 3749 5000
http://www.astrazeneca.co.uk
Group companies: AstraZeneca PLC
Name | Category and Sector |
---|---|
Astrazeneca Treasury BV | |
AstraZeneca AB
![]() AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. |
Miscellaneous Commercial Services
|
AstraZeneca Employee Share Trust Ltd.
![]() AstraZeneca Employee Share Trust Ltd. Miscellaneous Commercial ServicesCommercial Services Part of AstraZeneca PLC, AstraZeneca Employee Share Trust Ltd. is a British company that provides business support services. The company is located in the UK. |
Miscellaneous Commercial Services
|
AstraZeneca UK Ltd.
![]() AstraZeneca UK Ltd. Miscellaneous Commercial ServicesCommercial Services AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom. |
Miscellaneous Commercial Services
|
Alexion Pharmaceuticals, Inc. /New/ |
Other Pharmaceuticals
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
+0.13% | -3.57% | -16.40% | +0.50% | 217B | ||
-2.84% | -6.91% | -13.71% | +148.70% | 685B | ||
-0.62% | -4.65% | +0.70% | -14.77% | 360B | ||
-0.10% | -3.02% | +8.75% | +25.58% | 327B | ||
-2.81% | -7.21% | -53.24% | +21.17% | 326B | ||
0.00% | -1.10% | +1.80% | -15.12% | 255B | ||
+0.02% | -1.27% | -0.90% | +21.63% | 228B | ||
-0.29% | -3.24% | -39.52% | -11.33% | 199B | ||
-0.06% | -2.00% | -6.11% | +20.48% | 156B | ||
+0.38% | -2.32% | -13.59% | -51.15% | 136B | ||
Average | -0.63% | -4.16% | -13.22% | +14.57% | 288.83B | |
Weighted average by Cap. | -1.08% | -4.82% | -13.02% | +37.02% |
Sector

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AZN Stock
- Company AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions